Nicotine pouches are quickly becoming one of the most talked-about reduced-risk products in international efforts towards tobacco harm reduction (THR). Sitting somewhere in between traditional nicotine replacement therapies (NRTs) and contemporary vaping products, they serve as a smoke-free, tobacco-free product that could take on an important role in helping smokers transition away from combustible cigarette use.
But, like many safer nicotine substitutes, their course is increasingly being determined by regulation rather than science. Politicians across the world, from North America to Europe, are struggling with how to regulate these new products — often in ways that can end up restricting their potential to improve public health.
The small, discreet sachets deliver nicotine through the gum without using combustion, vapour or smoke. Because they use no tobacco leaf and emit no inhaled emissions, they miss out on the main perpetrator of smoking-related disease: combustion.
This distinction is critical. The evidence across the field of tobacco control has been consistent for decades: It is not the nicotine itself that is responsible for most of the harmful toxicants in tobacco, but rather it is the act of burning tobacco.
Why nicotine pouches?
Pouches also offer practical advantages. They are completely odourless and do not need to be charged or serviced, and can be used in situations where smoking or vaping would not work. For some users, they offer a familiar nicotine experience but without the behavioural cues of smoking.
Data from Sweden, where such oral nicotine products have been popular for several decades, leave us with undeniable evidence on their efficacy. Today, Sweden has one of the world’s lowest smoking and cancer rates as a result.
A wider classification of smoke-free nicotine products (SNPS) is also supported by clinical and behavioural research. Numerous studies published in journals like Nicotine & Tobacco Research and Addiction have indicated the effectiveness of smokeless nicotine delivery systems for smoking cessation and sustained abstinence, especially when used alongside behavioural support, compared to conventional NRT.
Nicotine pouches are newer but have the same key characteristics as other SNPs: controlled nicotine delivery, reduced exposure to toxicants and user preference. For smokers who find patches or gum maddening, and/or wish to avoid inhalation altogether, pouches could be an important added channel away from cigarettes.
Same product, different trajectories
Despite this great potential, their access remains inconsistent. Regulatory decisions in Canada have ignited increasing debate.
In 2023, Health Canada approved the marketing of some nicotine pouches as a natural health product. However, follow-up restrictions in 2024 limited their availability to pharmacy counters, tamed nicotine strength and reduced flavour options. Tobacco harm reduction experts believe these measures are placing unnecessary hurdles on adult smokers.
In fact, more European countries are becoming open to the products. Portugal seems poised to be the next country to legalise nicotine pouches after regulatory approval, following a change in local legislation that allows their sale. This expansion reflects growing realisation that nicotine pouches are their own thing: Not combustible tobacco, and also different from traditional oral tobacco products like snus. As a result, many policymakers have begun looking to apply more tailored regulatory frameworks rather than blanket restrictions.
The European discussions coincide with wider debates on reviewing nicotine taxation and product directives—decisions that could greatly shape the future availability and affordability of reduced-risk alternatives. And while no public health authority asserts that nicotine pouches are completely risk-free, relative risk is the essential component in harm reduction. Their status as reduced-risk products has been confirmed through toxicological analysis and risk assessment in several studies.
Policymakers scramble to restrict SNPs, but leave cigarettes widely available
One of the real challenges with nicotine pouches (and THR in general) is policy misalignment. Whenever regulations do not reflect differences in risk, unintended consequences usually ensue. And making lower-risk products less accessible than cigarettes sends mixed messages to consumers. It may also reduce the incentive to switch, especially among price-sensitive groups or those who face access barriers.
Given that (ironically) cigarettes are still widely accessible in most markets despite being the top cause of avoidable death, overly stringent policies may backfire by favouring the very products that are most harmful.
The importance of having a wide variety of cessation tools available
Overall, nicotine pouches probably aren’t a magic bullet. The use of different products works differently for different smokers — with vapes, heated tobacco, NRT and oral products. And this is the whole point. Where harm reduction shines is in offering menu options that cater to a variety of needs. In fact, pouches are likely to serve an important niche — those who want a discreet, smoke-free and non-inhaled option.
The point is becoming increasingly clear from the global experience with tobacco harm reduction: as soon as smokers have access to potentially less harmful alternatives that don’t stink, many will choose them. Nicotine pouches are an extension of this trend. And although more long-term research will ultimately clarify their role, the current evidence suggests that they have something meaningful to add to smoking cessation efforts. Limiting access risks slowing progress, distorting markets, and ultimately prolonging cigarette use.
